A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium

Trial Profile

A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Rucaparib (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Endometrial cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 04 May 2018 Planned initiation date changed from 1 Apr 2018 to 31 May 2018.
    • 28 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top